Literature DB >> 20858768

Lack of adrenomedullin in the central nervous system results in apparently paradoxical alterations on pain sensitivity.

Ana P Fernández1, Julia Serrano, Ricardo Martínez-Murillo, Alfredo Martínez.   

Abstract

Adrenomedullin (AM) is a regulatory peptide, coded by the adm gene, which is involved in numerous physiological processes, including pain sensitivity. Previous studies have shown that intrathecal injection of AM induced hyperalgesia in the rat. Here, we explore pain sensitivity in a mouse conditional knockout for adm in neurons of the central nervous system, including the spinal cord and dorsal root ganglia. Double immunofluorescence in wild-type (WT) animals shows that AM immunoreactivity is found in calcitonin gene-related peptide-positive neurons of the dorsal root ganglia but not in neurons that bind isolectin B4. Mice lacking adm had modified expression of canonical sensorial neuropeptides, having significantly more calcitonin gene-related peptide and less substance P and enkephalin than their WT littermates. Furthermore, the spinal cord of adm knockout mice expressed higher levels of the AM receptor components, suggesting a compensation attempt to deal with the lack of afferent AM signaling. Behavioral nociceptive tests also found differences between genotypes. In the tail-flick test, which measures mostly spinal reflexes, the adm-null animals had a longer latency than their WT counterparts. On the other hand, in the hotplate test, which requires encephalic processing, mice lacking adm had shorter latencies than normal littermates. These results suggest that AM acts as a nociceptive modulator in spinal reflexes, whereas it may have an analgesic function at higher cognitive levels. This study confirms the important role of AM in pain sensitivity processing but unveils a more complex scenario than previously surmised.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858768     DOI: 10.1210/en.2010-0121

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

1.  The neuronal oxygen-sensing pathway controls postnatal vascularization of the murine brain.

Authors:  Emil Nasyrov; Karen A Nolan; Roland H Wenger; Hugo H Marti; Reiner Kunze
Journal:  FASEB J       Date:  2019-08-30       Impact factor: 5.191

Review 2.  CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

Authors:  C S Walker; D L Hay
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

3.  Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice.

Authors:  Xin Luo; Wai Lydia Tai; Liting Sun; Qiu Qiu; Zhengyuan Xia; Sookja Kim Chung; Chi Wai Cheung
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

Review 4.  Adrenomedullin and tumour microenvironment.

Authors:  Ignacio M Larráyoz; Sonia Martínez-Herrero; Josune García-Sanmartín; Laura Ochoa-Callejero; Alfredo Martínez
Journal:  J Transl Med       Date:  2014-12-05       Impact factor: 5.531

5.  Adrenomedullin Contributes to Age-Related Memory Loss in Mice and Is Elevated in Aging Human Brains.

Authors:  Ignacio M Larrayoz; Hilda Ferrero; Eva Martisova; Francisco J Gil-Bea; María J Ramírez; Alfredo Martínez
Journal:  Front Mol Neurosci       Date:  2017-11-15       Impact factor: 5.639

6.  Development of chimeric and bifunctional antagonists for CLR/RAMP receptors.

Authors:  Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

7.  Adrenomedullin as a growth and cell fate regulatory factor for adult neural stem cells.

Authors:  Sonia Martínez-Herrero; Ignacio M Larráyoz; Laura Ochoa-Callejero; Josune García-Sanmartín; Alfredo Martínez
Journal:  Stem Cells Int       Date:  2012-09-24       Impact factor: 5.443

Review 8.  Beyond CGRP: The calcitonin peptide family as targets for migraine and pain.

Authors:  Tayla A Rees; Erica R Hendrikse; Debbie L Hay; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2021-07-27       Impact factor: 9.473

9.  Prevention of Bone Loss in a Model of Postmenopausal Osteoporosis through Adrenomedullin Inhibition.

Authors:  Sonia Martínez-Herrero; Ignacio M Larrayoz; Laura Ochoa-Callejero; Luis J Fernández; Alexis Allueva; Ignacio Ochoa; Alfredo Martínez
Journal:  Front Physiol       Date:  2016-06-30       Impact factor: 4.566

Review 10.  Adrenomedullin: an important participant in neurological diseases.

Authors:  Feng-Jiao Li; Si-Ru Zheng; Dong-Mei Wang
Journal:  Neural Regen Res       Date:  2020-07       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.